OncoMatch/Clinical Trials/NCT06915246
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
Is NCT06915246 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including VI-0609 and BiCNU for lymphoma.
Treatment: VI-0609 · BiCNU — A phase 2 multicenter study of VI-0609 vs BiCNU in the BEAM high-intensity conditioning regimen for AHCT in subjects with lymphomas.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Prior therapy
Must have received: salvage cytoreductive chemotherapy
Recovery from non-hematologic toxicities of salvage cytoreductive chemotherapy to ≤ grade 2
Cannot have received: high-dose chemotherapy with autologous stem cell transplant
Prior high-dose chemotherapy with autologous stem cell transplant
Cannot have received: allogeneic transplantation
prior allogeneic transplantation
Cannot have received: external beam radiation therapy
Exception: dose-limiting radiation to a critical organ
Significant prior external beam dose-limiting radiation to a critical organ
Lab requirements
Cardiac function
lvef ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Phoenix · Goodyear, Arizona
- City of Hope National Medical Center · Duarte, California
- City of Hope Atlanta · Newnan, Georgia
- City of Hope Chicago · Zion, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify